Skip to content

Compare the effect of Vidaryadi modak and Priyaladi modak in Underweight children

Prospective comparative open clinical study of brumhana effect of vidaryadi modak and priyaladi modak in balkarshya with special reference to underweight children - NIL

Status
Active, not recruiting
Phases
Phase 2Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2023/10/058297
Enrollment
92
Registered
2023-10-05
Start date
Unknown
Completion date
Unknown
Last updated
2023-10-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E639- Nutritional deficiency, unspecified

Interventions

None listed

Sponsors

Dr Megha Deepak Posugade
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1 Subjects within age group 6 to 12 years will be included in the study irrespective of sex socioeconomic status caste and religion 2 The weight of children is 60 to 80 percent of ideal weight expected for their age and without oedema

Exclusion criteria

Exclusion criteria: Underweight children associated with 1 Any infective diseases like Rubella syphilis Hepatitis B HIV CMV Toxoplasmosis 2 Children with chronic systemic diseases like Chronic Renal Failure 3 The weight of children below 60 percent of ideal weight expected for their age 4 Protein Energy Malnutrition Kwashiorkar Marasmus and Marasmic Kwashiorkar

Design outcomes

Primary

MeasureTime frame
To compare the weight gain effect of Vidaryadi Modak and Priyaladi Modak in BalkarshyaTimepoint: 8 weeks

Secondary

MeasureTime frame
To compare the changes in general appearance of child and weight gain effect by consuming Vidaryadi Modak & Priyaladi Modak in balkarshyaTimepoint: 8 weeks

Countries

India

Contacts

Public ContactDr Nareshkumar Keshav Babar

Hon Shri Annasaheb Dange Ayurved Hospital and Research Centre Ashta

dr.nareshbabar@gmail.com7507595454

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026